

**Summary of full Sobi data to be presented at ACR 2025:**

<b>NASP</b>	
<p>Nanoencapsulated Sirolimus plus Pegadricase Reduced Disease Burden in Patients with Uncontrolled Gout: Results from the Phase 3 DISSOLVE Trials</p> <p><b>Presenting Author:</b> <i>Puja P. Khanna, MD, MPH, Division of Rheumatology, University of Michigan, Ann Arbor, MI</i></p>	<p><b>Oral Presentation</b></p> <p>Session: Abstracts: Metabolic &amp; Crystal Arthropathies – Basic &amp; Clinical Science</p> <p>Date: Tuesday 28 October</p> <p>Session time: 1:00 PM - 2:30 PM CT</p> <p>Presentation time: 1:30 PM - 1:45 PM CT</p>
<p>Nanoencapsulated Sirolimus plus Pegadricase Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies*)</p> <p><b>Presenting Author:</b> <i>Angelo Gaffo, MD, Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL</i></p>	<p><b>Oral Presentation</b></p> <p>Session: Abstracts: Metabolic &amp; Crystal Arthropathies – Basic &amp; Clinical Science</p> <p>Date: Tuesday 28 October</p> <p>Session time: 1:00 PM - 2:30 PM CT</p> <p>Presentation time: 1:45 PM - 2:00 PM CT</p>
<p>Nanoencapsulated Sirolimus plus Pegadricase Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study</p> <p><b>Presenting Author:</b> <i>Alan Kivitz, MD, Altoona Center for Clinical Research, Duncansville, PA</i></p>	<p><b>Poster Presentation</b></p> <p>Session: Metabolic &amp; Crystal Arthropathies – Basic &amp; Clinical Science Poster I</p> <p>Date: Monday 27 October</p> <p>Presentation time: 10:30 AM - 12:30 PM CT</p>
<p>Characterisation of Infusion Reactions Within 1 Hour of Treatment with Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results from the Phase 3 DISSOLVE I and DISSOLVE II Trials</p> <p><b>Presenting Author:</b> <i>Herbert S.B. Baraf, MD, FACP, MACR, The Center for Rheumatology and Bone Research, Wheaton, MD</i></p>	<p><b>Poster Presentation</b></p> <p>Session: Metabolic &amp; Crystal Arthropathies – Basic &amp; Clinical Science Poster II</p> <p>Date: Tuesday 28 October</p> <p>Presentation time: 10:30 AM - 12:30 PM CT</p>
<p>Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies*</p> <p><b>Presenting Author:</b> <i>Herbert S.B. Baraf, MD, FACP, MACR, The Center for Rheumatology and Bone Research, Wheaton, MD</i></p>	<p><b>Poster Presentation</b></p> <p>Session: Poster Session C, (1990–2014) Metabolic &amp; Crystal Arthropathies – Basic &amp; Clinical Science Poster II</p> <p>Date: Tuesday 28 October</p> <p>Presentation time: 10:30 AM - 12:30 PM CT</p>
<p>Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study</p> <p><b>Presenting Author:</b> <i>Angelo Gaffo, MD, Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL</i></p>	<p><b>Poster Presentation</b></p> <p>Session: Patient Outcomes, Preferences, &amp; Attitudes Poster II</p> <p>Date: Monday 27 October</p> <p>Presentation time: 10:30 AM - 12:30 PM CT</p>
<p>A Real-World Survey on Physicians' Perspectives of Uncontrolled Gout and Gout Management Practices</p> <p><b>Presenting Author:</b> <i>John Botson, MD, RPh, CCD, Orthopedic Physicians, Anchorage, AK</i></p>	<p><b>Poster Presentation</b></p> <p>Session: Health Services Research Poster III</p> <p>Date: Tuesday 28 October</p> <p>Presentation time: 10:30 AM - 12:30 PM CT</p>
<p>The Care Pathway and Treatment Patterns in Patients with Uncontrolled Gout: A Real-World Survey of Physicians in the United States</p>	<p><b>Poster Presentation</b></p> <p>Session: Health Services Research Poster II</p> <p>Date: Monday 27 October</p> <p>Presentation time: 10:30 AM - 12:30 PM CT</p>

<b>Presenting Author:</b> John Albert, MD, Rheumatic Disease Center, Glendale, WI	
Management of Uncontrolled Gout Among Rheumatologists: Findings from a Medical Chart Audit  <b>Presenting Author:</b> Hyon Choi, MD, MPH, DrPH, Massachusetts General Hospital, Boston, MA	<b>Poster Presentation</b> Session: ARP Posters I Date: Tuesday 28 October Presentation time: 10:30 AM - 12:30 PM CT
<b>Gamifant (emapalumab-lzsg)</b>	
Baseline Pharmacodynamic Markers and Response to emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still's Disease: Results from a Pooled Analysis of Two Prospective Trials  <b>Presenting Author:</b> Ed Behrens, MD, Chief, Division of Rheumatology, Children's Hospital of Philadelphia	<b>Oral Presentation</b> Session: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I: Focus on Auto-Inflammatory Diseases Date: Sunday 26 October Session time: 1:00 PM - 2:30 PM CT Presentation time: 1:45 PM - 2:00 PM CT
Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still's Disease: Results from a Pooled Analysis of Two Prospective Trials  <b>Presenting Author:</b> Alexei Grom, MD, Research Director, Division of Rheumatology, Cincinnati Children's Hospital	<b>Oral Presentation</b> Session: Abstracts: Pediatric Rheumatology – Clinical I Date: Monday 27 October Session time: 1:00 PM - 2:30 PM CT Presentation time: 1:45 PM - 2:00 PM CT
Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still's Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still's Disease (AOSD): Analysis of a US National Administrative Claims Database  <b>Presenting Author:</b> Michael Marrone, Director of Epidemiology and Biostatistics, Sobi	<b>Poster Presentation</b> Session: Health Services Research Poster III Date: Tuesday 28 October Presentation Time: 10:30 AM - 12:30 PM CT
<b>Vonjo (Pacritinib)</b>	
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)*  <b>Presenting Author:</b> Dr. Matthew J. Koster, Assistant Professor of Medicine, Mayo Clinic Rochester	<b>Oral Presentation</b> Session: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I: Focus on Auto-Inflammatory Diseases Date: Sunday 26 October Session time: 1:00 PM - 2:30 PM CT Presentation time: 1:00 PM - 1:15 PM CT
PAXIS: A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome*  <b>Presenting Author:</b> Dr. David B. Beck, MD, PhD, Division of Rheumatology, NYU Langone	<b>Oral Presentation</b> Session: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye Date: Wednesday 29 October Session time: 11:30 AM - 1:00 PM CT Presentation time: 11:30 AM - 11:45 AM CT
Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research*  <b>Presenting Author:</b> Dr. Marcela A. Ferrada, MD, Clinical Associate Professor, University of Maryland School of Medicine	<b>Poster Presentation</b> Session: Miscellaneous Rheumatic & Inflammatory Diseases Poster I Date: Sunday 26 October Presentation time: 10:30 AM - 12:30 PM CT
<b>*Signifies encore data presentation</b>	